Announcements Trials
Browse Landscape

Status

Completed 6Unknown 1

Sponsor Class

OTHER 26INDUSTRY 7OTHER_GOV 2NIH 1

Study Type

Interventional 9Observational 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Breast Neoplasms 467Neoplasms 315Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 207Lung Neoplasms 176Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 59Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

Dutasteride 2Therapeutics 1Adrenergic alpha-Antagonists 15-alpha Reductase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Prostatic Hyperplasia × Clear all
NCT04272216 2025-09-09

RAVI Registry

Terumo Medical Corporation

Completed
99 enrolled 15 charts
Genitourinary

Arteriovenous Malformations, Leiomyoma, Prostatic Hyperplasia

NCT00883909 2017-07-11

ARI103094-Follow-Up Study for REDUCE Study Subjects

GlaxoSmithKline

Completed
2,795 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01337258 2017-05-30

Economic Analyses of the REDUCE Trial

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

NCT01371513 2017-05-22

RESPECT

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01767363 2016-11-09

WEUSKOP5723: Prostate Cancer Study

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Prostatic Hyperplasia

NCT00822952 2014-03-31

PMI

Artann Laboratories

Completed
71 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT00400894 2007-02-05

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

ProteoSys AG

Unknown
750 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡